Skip to content
10-Q

Quarterly Report

Nuvectis Pharma, Inc. NVCT

0001104659-26-055318

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 26.53M sh
Shares Diluted Q1 2026 · Mar 31, 2026 23.41M sh
Shares Diluted Q1 2026 · Mar 31, 2025 19.94M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$6.51M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.17M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $25.13M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $31.63M
Stockholders Equity Q1 2026 · Mar 31, 2026 $14.22M
Stockholders Equity Q1 2026 · Dec 31, 2025 $18.41M
Stockholders Equity Q1 2026 · Mar 31, 2025 $20.95M
Stockholders Equity Q1 2026 · Dec 31, 2024 $9.71M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.18M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.3M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.18M
Total Liabilities Q1 2026 · Dec 31, 2025 $13.3M
Current Assets Q1 2026 · Mar 31, 2026 $25.4M
Current Assets Q1 2026 · Dec 31, 2025 $31.71M
Total Assets Q1 2026 · Mar 31, 2026 $25.4M
Total Assets Q1 2026 · Dec 31, 2025 $31.71M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.26
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.27
Eps Basic Q1 2026 · Mar 31, 2026 −$0.26
Eps Basic Q1 2026 · Mar 31, 2025 −$0.27
Sga Expense Q1 2026 · Mar 31, 2026 $2.15M
Sga Expense Q1 2026 · Mar 31, 2025 $1.89M
Rd Expense Q1 2026 · Mar 31, 2026 $4.11M
Rd Expense Q1 2026 · Mar 31, 2025 $3.68M
Net Income Q1 2026 · Mar 31, 2026 −$6.05M
Net Income Q1 2026 · Mar 31, 2025 −$5.33M
Operating Income Q1 2026 · Mar 31, 2026 −$6.26M
Operating Income Q1 2026 · Mar 31, 2025 −$5.57M